<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27219325</article-id><article-id pub-id-type="pmc">4878764</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0156471</article-id><article-id pub-id-type="publisher-id">PONE-D-16-19926</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Trajman</surname><given-names>Anete</given-names></name></contrib><contrib contrib-type="author"><name><surname>Durovni</surname><given-names>Betina</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saraceni</surname><given-names>Valeria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Menezes</surname><given-names>Alexandre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cordeiro-Santos</surname><given-names>Marcelo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cobelens</surname><given-names>Frank</given-names></name></contrib><contrib contrib-type="author"><name><surname>Van den Hof</surname><given-names>Susan</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>24</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>5</issue><elocation-id>e0156471</elocation-id><permissions><copyright-statement>&#x000a9; 2016 Trajman et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Trajman et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0156471.pdf"/><related-article id="d36e104" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1371/journal.pone.0123252">
<article-title>Impact on Patients&#x02019; Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial</article-title>
</related-article><counts><fig-count count="0"/><table-count count="2"/><page-count count="3"/></counts></article-meta></front><body><p>There are a number of errors in the &#x0201c;aOR (95%CI)&#x0201d; columns for Tables <xref ref-type="table" rid="pone.0156471.t001">3</xref> and <xref ref-type="table" rid="pone.0156471.t002">4</xref>. During secondary analysis, the authors observed 128 duplicate entries in the study database among 4054 included in the analyses. Despite observing the random distribution of duplicates, the authors performed all analyses again after removal of the 128 duplicates (leaving 3926 patients in the analyses) and found negligible effect on the outcome measures: aOR for arm associated with unfavourable outcome now 0.93 (0.80&#x02013;1.09) compared to 0.93 (0.79&#x02013;1.08) in the original article; while aOR for TB-attributed deaths is 0.69 (0.46&#x02013;1.04) compared to 0.65 (0.44&#x02013;0.97). Even though the 95% confidence interval of the aOR for TB attributed death now includes 1, the difference with the originally reported aOR and the width of its confidence interval are minimal, hence the conclusions from the results remain unchanged. Please see the correct Tables <xref ref-type="table" rid="pone.0156471.t001">3</xref> and <xref ref-type="table" rid="pone.0156471.t002">4</xref> here.</p><table-wrap id="pone.0156471.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0156471.t001</object-id><label>Table 3</label><caption><title>Characteristics associated with unfavourable outcomes in a multilevel logistic regression model</title></caption><alternatives><graphic id="pone.0156471.t001g" xlink:href="pone.0156471.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Unfavourable<xref ref-type="table-fn" rid="t001fn003">&#x02020;</xref> (n = 1181)</th><th align="center" rowspan="1" colspan="1">Successful (n = 2745)</th><th align="center" rowspan="1" colspan="1">crude OR (95%CI)</th><th align="center" rowspan="1" colspan="1">aOR (95%CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Sex</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">846 (33.2%)</td><td align="center" rowspan="1" colspan="1">1700 (66.8%)</td><td align="center" rowspan="1" colspan="1">1.5 (1.3&#x02013;1.8)</td><td align="center" rowspan="1" colspan="1">1.5 (1.3&#x02013;1.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">335 (24.3%)</td><td align="center" rowspan="1" colspan="1">1045 (75.7%)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Age group (years)</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;14</td><td align="center" rowspan="1" colspan="1">18 (19.8%)</td><td align="center" rowspan="1" colspan="1">73 (80.2%)</td><td align="center" rowspan="1" colspan="1">0.76 (0.44&#x02013;1.32)</td><td align="center" rowspan="1" colspan="1">0.69 (0.39&#x02013;1.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">15&#x02013;29</td><td align="center" rowspan="1" colspan="1">704 (33.8%)</td><td align="center" rowspan="1" colspan="1">1378 (66.2%)</td><td align="center" rowspan="1" colspan="1">1.6 (1.3&#x02013;2.0)</td><td align="center" rowspan="1" colspan="1">1.6 (1.2&#x02013;2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">30&#x02013;59</td><td align="center" rowspan="1" colspan="1">347 (26.9%)</td><td align="center" rowspan="1" colspan="1">943 (73.1%)</td><td align="center" rowspan="1" colspan="1">1.1 (0.90&#x02013;1.5)</td><td align="center" rowspan="1" colspan="1">1.1 (0.86&#x02013;1.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;60</td><td align="center" rowspan="1" colspan="1">112 (24.2%)</td><td align="center" rowspan="1" colspan="1">351 (75.8%)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>HIV status</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">452 (21.2%)</td><td align="center" rowspan="1" colspan="1">1675 (78.8%)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">171 (43.7%)</td><td align="center" rowspan="1" colspan="1">220 (56.3%)</td><td align="center" rowspan="1" colspan="1">2.9 (2.3&#x02013;3.7)</td><td align="center" rowspan="1" colspan="1">3.1 (2.4&#x02013;3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">558 (39.6%)</td><td align="center" rowspan="1" colspan="1">850 (60.4%)</td><td align="center" rowspan="1" colspan="1">2.6 (2.2&#x02013;3.0)</td><td align="center" rowspan="1" colspan="1">2.6 (2.2&#x02013;3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>City</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Manaus</td><td align="center" rowspan="1" colspan="1">222 (28.5%)</td><td align="center" rowspan="1" colspan="1">556 (71.5%)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rio</td><td align="center" rowspan="1" colspan="1">959 (30.5%)</td><td align="center" rowspan="1" colspan="1">2189 (69.5%)</td><td align="center" rowspan="1" colspan="1">1.1 (0.81&#x02013;1.4)</td><td align="center" rowspan="1" colspan="1">1.3 (1.01&#x02013;1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Type of diagnosis</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Confirmed<xref ref-type="table-fn" rid="t001fn001">*</xref></td><td align="center" rowspan="1" colspan="1">875 (30.9%)</td><td align="center" rowspan="1" colspan="1">1960 (69.1%)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinically diagnosed, negative test<xref ref-type="table-fn" rid="t001fn002"><sup>&#x000a7;</sup></xref></td><td align="center" rowspan="1" colspan="1">198 (28.5%)</td><td align="center" rowspan="1" colspan="1">496 (71.5%)</td><td align="center" rowspan="1" colspan="1">0.89 (0.73&#x02013;1.1)</td><td align="center" rowspan="1" colspan="1">0.86 (0.71&#x02013;1.04)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinically diagnosed, no test result</td><td align="center" rowspan="1" colspan="1">108 (27.2%)</td><td align="center" rowspan="1" colspan="1">289 (72.8%)</td><td align="center" rowspan="1" colspan="1">0.82 (0.65&#x02013;1.04)</td><td align="center" rowspan="1" colspan="1">0.76 (0.59&#x02013;0.97)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Arm</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">556 (31.3%)</td><td align="center" rowspan="1" colspan="1">1221 (68.7%)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td><td align="center" rowspan="1" colspan="1">1 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1">Intervention</td><td align="center" rowspan="1" colspan="1">625 (29.1%)</td><td align="center" rowspan="1" colspan="1">1524 (70.9%)</td><td align="center" rowspan="1" colspan="1">0.92 (0.79&#x02013;1.06)</td><td align="center" rowspan="1" colspan="1">0.93 (0.80&#x02013;1.09)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>*Positive smear in baseline arm and positive Xpert in intervention arm.</p></fn><fn id="t001fn002"><p><sup>&#x000a7;</sup>Negative smear in baseline arm and negative Xpert in intervention arm.</p></fn><fn id="t001fn003"><p>&#x02020;Unfavourable = loss to follow up, death from any cause, transfer out and resistance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0156471.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0156471.t002</object-id><label>Table 4</label><caption><title>Characteristics associated with TB-attributed death in a multilevel logistic regression model</title></caption><alternatives><graphic id="pone.0156471.t002g" xlink:href="pone.0156471.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">TB-attributed death (n = 119)</th><th align="center" rowspan="1" colspan="1">Successful (n = 2745)</th><th align="center" rowspan="1" colspan="1">crude OR (95%CI)</th><th align="center" rowspan="1" colspan="1">aOR (95%CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Sex</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">83 (4.7%)</td><td align="center" rowspan="1" colspan="1">1700 (95.3%)</td><td align="center" rowspan="1" colspan="1">1.4 (0.95&#x02013;2.1)</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">36 (3.3%)</td><td align="center" rowspan="1" colspan="1">1045 (96.7%)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Age group (years)</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;14</td><td align="center" rowspan="1" colspan="1">1 (1.3%)</td><td align="center" rowspan="1" colspan="1">73 (98.7%)</td><td align="center" rowspan="1" colspan="1">0.20 (0.03&#x02013;1.6)</td><td align="center" rowspan="1" colspan="1">0.14 (0.02&#x02013;1.01)</td></tr><tr><td align="left" rowspan="1" colspan="1">15&#x02013;29</td><td align="center" rowspan="1" colspan="1">49 (3.4%)</td><td align="center" rowspan="1" colspan="1">1378 (96.6%)</td><td align="center" rowspan="1" colspan="1">0.54 (0.33&#x02013;0.9)</td><td align="center" rowspan="1" colspan="1">0.44 (0.26&#x02013;0.76)</td></tr><tr><td align="left" rowspan="1" colspan="1">30&#x02013;59</td><td align="center" rowspan="1" colspan="1">46 (4.6%)</td><td align="center" rowspan="1" colspan="1">943 (95.4%)</td><td align="center" rowspan="1" colspan="1">0.74 (0.44&#x02013;1.2)</td><td align="center" rowspan="1" colspan="1">0.57 (0.33&#x02013;0.98)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;60</td><td align="center" rowspan="1" colspan="1">23 (6.1%)</td><td align="center" rowspan="1" colspan="1">351 (93.9%)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>HIV status</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">25 (1.5%)</td><td align="center" rowspan="1" colspan="1">1675 (98.5%)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">44 (16.7%)</td><td align="center" rowspan="1" colspan="1">220 (83.3%)</td><td align="center" rowspan="1" colspan="1">14.0 (8.1&#x02013;24.2)</td><td align="center" rowspan="1" colspan="1">16.1 (9.2&#x02013;28.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="center" rowspan="1" colspan="1">50 (5.6%)</td><td align="center" rowspan="1" colspan="1">850 (94.4%)</td><td align="center" rowspan="1" colspan="1">4.1 (2.4&#x02013;6.7)</td><td align="center" rowspan="1" colspan="1">4.3 (2.6&#x02013;7.1)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>City</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Manaus</td><td align="center" rowspan="1" colspan="1">21 (3.6%)</td><td align="center" rowspan="1" colspan="1">556 (96.4%)</td><td align="center" rowspan="1" colspan="1">1.2 (0.73&#x02013;1.9)</td><td align="center" rowspan="1" colspan="1">1.96 (1.01&#x02013;3.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rio</td><td align="center" rowspan="1" colspan="1">98 (4.3%)</td><td align="center" rowspan="1" colspan="1">2189 (95.7%)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Type of diagnosis</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Confirmed<xref ref-type="table-fn" rid="t002fn002">*</xref></td><td align="center" rowspan="1" colspan="1">81 (4.0%)</td><td align="center" rowspan="1" colspan="1">1960 (96.0%)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Clinically diagnosed, negative test<xref ref-type="table-fn" rid="t002fn003"><sup>&#x000a7;</sup></xref></td><td align="center" rowspan="1" colspan="1">25 (4.8%)</td><td align="center" rowspan="1" colspan="1">496 (95.2%)</td><td align="center" rowspan="1" colspan="1">1.2 (0.77&#x02013;1.9)</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinically diagnosed, no test result</td><td align="center" rowspan="1" colspan="1">13 (4.3%)</td><td align="center" rowspan="1" colspan="1">289 (95.7%)</td><td align="center" rowspan="1" colspan="1">1.1 (0.59&#x02013;2.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Arm</italic></bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">68 (5.3%)</td><td align="center" rowspan="1" colspan="1">1221 (94.7%)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td><td align="center" rowspan="1" colspan="1">1.0 (reference)</td></tr><tr><td align="left" rowspan="1" colspan="1">Intervention</td><td align="center" rowspan="1" colspan="1">51 (3.2%)</td><td align="center" rowspan="1" colspan="1">1524 (96.8%)</td><td align="center" rowspan="1" colspan="1">0.60 (0.42&#x02013;0.85)</td><td align="center" rowspan="1" colspan="1">0.69 (0.46&#x02013;1.04)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>OR = odds ratio, aOR = adjusted odds ratio</p></fn><fn id="t002fn002"><p>*Positive smear in baseline arm and positive Xpert in intervention arm</p></fn><fn id="t002fn003"><p><sup>&#x000a7;</sup> Negative smear in baseline arm and negative Xpert in intervention arm</p></fn></table-wrap-foot></table-wrap></body><back><ref-list><title>Reference</title><ref id="pone.0156471.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Trajman</surname><given-names>A</given-names></name>, <name><surname>Durovni</surname><given-names>B</given-names></name>, <name><surname>Saraceni</surname><given-names>V</given-names></name>, <name><surname>Menezes</surname><given-names>A</given-names></name>, <name><surname>Cordeiro-Santos</surname><given-names>M</given-names></name>, <name><surname>Cobelens</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Impact on Patients&#x02019; Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial</article-title>. <source>PLoS ONE</source>
<volume>10</volume>(<issue>4</issue>): <fpage>e0123252</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0123252">10.1371/journal.pone.0123252</ext-link></comment>
<pub-id pub-id-type="pmid">25915745</pub-id></mixed-citation></ref></ref-list></back></article>